DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,743,333 | -1.9% | 15,088 | -5.1% | 2.83% | +9.1% |
| Q2 2023 | $3,814,320 | -7.9% | 15,893 | -3.3% | 2.59% | -9.3% |
| Q1 2023 | $4,140,513 | -6.8% | 16,428 | -1.8% | 2.86% | -3.4% |
| Q4 2022 | $4,441,007 | -3.4% | 16,732 | -6.0% | 2.96% | +3.9% |
| Q3 2022 | $4,596,000 | +6.7% | 17,793 | +4.8% | 2.84% | +7.8% |
| Q2 2022 | $4,306,000 | -10.8% | 16,985 | +3.3% | 2.64% | +1.7% |
| Q1 2022 | $4,825,000 | -4.0% | 16,449 | +7.7% | 2.59% | -3.1% |
| Q4 2021 | $5,025,000 | +17.5% | 15,273 | +8.7% | 2.68% | +35.9% |
| Q3 2021 | $4,277,000 | +4.1% | 14,049 | -8.2% | 1.97% | -4.2% |
| Q2 2021 | $4,107,000 | +19.0% | 15,304 | -0.2% | 2.06% | +4.2% |
| Q1 2021 | $3,451,000 | +4.0% | 15,334 | +2.7% | 1.98% | -14.4% |
| Q4 2020 | $3,317,000 | +6.8% | 14,934 | +8.9% | 2.31% | -1.5% |
| Q3 2020 | $3,107,000 | +20.3% | 13,714 | -6.1% | 2.34% | -0.7% |
| Q2 2020 | $2,582,000 | +29.4% | 14,599 | +1.3% | 2.36% | +6.8% |
| Q1 2020 | $1,995,000 | -10.2% | 14,417 | -0.4% | 2.21% | -2.1% |
| Q4 2019 | $2,221,000 | – | 14,474 | – | 2.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |